

# **Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure**

University of California at San Diego Medical Center, San Diego, California, United States

San Diego Cardiac Center, San Diego, California, United States

Shands Hospital at University of Florida, Gainesville, Florida, United States

Northwestern University, Chicago, Illinois, United States

University of Chicago Medical Center, Chicago, Illinois, United States

Mid America Heart Institute, Saint Luke's Hospital, Kansas City, Missouri, United States

St. Louis University Hospital, St. Louis, Missouri, United States

University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States

Mount Sinai Medical Center, New York, New York, United States

Columbia University Hospital, New York, New York, United States

Wake Forest University, Winston-Salem, North Carolina, United States

University of Cincinnati, Cincinnati, Ohio, United States

MetroHealth Medical Center, Cleveland, Ohio, United States

Cleveland Clinic Foundation, Cleveland, Ohio, United States

Oregon Health and Science University, Portland, Oregon, United States

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center, Presbyterian-Shadyside Hospital, Pittsburgh, Pennsylvania, United States

Tennessee Center for Clinical Trials & Harton Regional Medical Center, Tullahoma, Tennessee, United States

Cardiopulmonary Research Science and Technology Institute, Medical City Dallas Hospital, Dallas, Texas, United States

Methodist Hospital, Houston, Texas, United States

Intermountain Medical Center, Murray, Utah, United States

University of Wisconsin, Madison, Wisconsin, United States

The study is divided into 2 parts. In the first part, the safety of the gene transfer agent

MYDICAR® will be evaluated. In the second part, the ability of MYDICAR® to improve heart function will be studied.